TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01177709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
Study: NCT03247465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image Fusion
Description: Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
Study: NCT01963377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 through nasal cannulae
Description: supplementation of O2 through nasal cannulae during bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 through nasal cannulae
Description: supplementation of O2 through nasal cannulae during bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2-channel
Description: supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2-channel
Description: supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
Study: NCT03287284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Low Level Laser Therapy
Description: Active application of Low Level Laser Therapy with a dose of 240 Joules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Resistance Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Resistance Training

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: Placebo application of Low Level Laser Therapy
Study: NCT05234086

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: InbioDerm + C plus advanced healing
Description: For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced healing
Description: Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
Study: NCT02683044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)
Description: Sessions of shocks to the body of the penis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)
Description: Sessions of shocks to the body of the penis
Study: NCT03442478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2D/3D Tomosynthesis
Study: NCT01133574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 120 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 1250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: low dose group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: high dose group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: low dose group 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: high dose group 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: placebo
Study: NCT02929550

Intervention type: OTHER
Intervention: Well-controlled
Description: Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l
Study: NCT01090908

Intervention type: DRUG
Intervention: Antibiotic
Study: NCT02123615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT01211236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of wound dressing made of bio-bags (vitapads) containing maggots

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of classical hydrogel/alginate wound dressing
Study: NCT01797341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT02149602

Intervention type: RADIATION
Intervention: Intensity modulated radiotherapy
Description: Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
Study: NCT04041440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clEAR auditory training
Description: Children play auditory brain training computer games
Study: NCT03243643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Description: HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
Study: NCT01356641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment alone
Description: Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Appendectomy either open or laparoscopic depending on the surgeon's preference
Study: NCT00003048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine Trihydrate
Description: Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
Study: NCT04418713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active video-games
Description: An intervention with active video-games to increase physical activity and improve body composition
Study: NCT06062940

Intervention type: BEHAVIORAL
Intervention: SHARE Approach
Description: The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.

Intervention type: BEHAVIORAL
Intervention: SHARE Approach
Description: The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
Study: NCT02917265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS for vagus stimulation
Description: TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS for sham stimulation
Description: TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
Study: NCT02891044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
Study: NCT03885804

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Quadratus lamborum dexmedetomidine intravenous
Description: Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
Study: NCT03885804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lamborum dexmedetomidine perineural group(
Description: Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
Study: NCT04404608

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood picture, bone marrow aspiration cytology
Description: none except the regular routine investigations in such cases

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood picture, bone marrow aspiration cytology
Description: none except the regular routine investigations in such cases

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood picture, bone marrow aspiration cytology
Description: none except the regular routine investigations in such cases
Study: NCT02430818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Study: NCT01199458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: 20 mikrogr/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
Study: NCT02966535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
Description: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
Description: Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
Study: NCT01821898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Budesonide
Description: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elimination diet
Description: This group will receive an elimination diet
Study: NCT00692640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
Study: NCT04000932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local platelet rich plasma (PRP) injection-T-Lab PRP kit
Description: Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local steroid injection-Diprospan ®, Schering Plough
Description: The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
Study: NCT02743715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS (transcranial direct current stimulation)
Description: An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
Study: NCT03290573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short peripheral venous catheter
Description: short peripheral venous catheter for infusion therapy in adult patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short peripheral venous catheter
Description: short peripheral venous catheter for infusion therapy in adult patients
Study: NCT03266185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter PICT
Description: Shorter post-infusion cooling time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter PICT
Description: Shorter post-infusion cooling time
Study: NCT03571984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving on ABC Plus
Description: The intervention has two components. CBT Moving on After Breast Cancer
Study: NCT02881008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Study: NCT02885727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
Study: NCT02441946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Administered orally
Study: NCT02123615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02131038

Intervention type: OTHER
Intervention: Medica device, drug-like
Description: Ectoin (R) Allergy Nasal Spray
Study: NCT01719224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elevated body position
Description: 45 degrees elevated upper body position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine body position
Description: non-elevated upper body position
Study: NCT04112940

Intervention type: OTHER
Intervention: Starch-based Thickened Liquids
Description: Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.

Intervention type: OTHER
Intervention: Xanthan-gum Thickened Liquids
Description: Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
Study: NCT01274065

Intervention type: GENETIC
Intervention: Genetic analysis
Description: The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
Study: NCT02548858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineorrhaphy
Description: Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Perineorrhaphy
Description: Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
Study: NCT03354130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Processed meat dietary intervention
Description: Randomized cross-over dietary intervention with 5 different diets
Study: NCT03068806

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
Study: NCT05264233

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: 50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable oil
Description: 50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
Study: NCT02757222

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalated Dose
Description: Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose
Description: CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy.